Archive for the 'Pleural' Category
Malignant pleural mesothelioma; mesothelioma of the lining of the lungs, or pleura.
July 22nd, 2008. Prevalence and Pattern of Lymph Node Metastasis in Malignant Pleural Mesothelioma
Conclusions: The pattern of nodal metastases may be different from that of lung cancer, and multicenter studies are needed to evaluate this observation.
July 11th, 2008. Incidence of atrial fibrillation after extrapleural pneumonectomy versus pleurectomy in patients with malignant pleural mesothelioma
The increased odds of having AF after EPP could be due to right heart stress caused by pneumonectomy. Increased right heart stress might not be sufficient to cause AF alone, but may be an important risk factor that warrants further investigation.
Posted in Determining Efficacy, Extrapleural Pneumonectomy (EPP), Full Archive, Pleural, Pleurectomy/decortication, Pneumonectomy, Surgery, Survival, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
July 9th, 2008. Malignant mesothelioma: current status and perspective in Japan and the world
In this context, combination therapy with surgery plus chemotherapy and/or radiotherapy is currently considered the standard treatment for patients with respectable MPM. A national survey of EPP was conducted recently in Japan, and a few multicenter clinical trials will start soon.
Posted in Chemotherapy, Diagnosis & Differentiation, Extrapleural Pneumonectomy (EPP), Full Archive, Pleural, Pleurectomy/decortication, Radiation, Staging, Surgery, thoracoscopy, Treatment, Trimodality Therapy, Type of Assessment:, Type of Mesothelioma: | No Comments »
July 1st, 2008. Morbidity, mortality, mean survival, and the impact of histology on survival after pleurectomy in 64 patients with malignant pleural mesothelioma
Conclusion: Our results show that pleurectomy can be performed as a means of palliation for advanced-stage disease with a low mortality rate and may, in fact, improve survival in patients with epithelial subtype as compared with historical controls in the literature with no surgical intervention.
Posted in Biphasic or Mixed, Determining Efficacy, Epithelioid, Extrapleural Pneumonectomy (EPP), Full Archive, Pleural, Sarcomatoid, Surgery, Survival, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
July 1st, 2008. Malignant mesothelioma with heterologous elements: clinicopathological correlation of 27 cases and literature review
Immunohistochemical labelling for cytokeratins is helpful in the distinction, but lack of labelling for cytokeratins in a spindle cell/sarcomatoid tumour does not exclude the diagnosis of mesothelioma, irrespective of the presence of heterologous elements. We suggest that if the anatomical distribution conforms to that of mesothelioma, a diagnosis of heterologous mesothelioma should be made in preference to a diagnosis of primary pleural osteosarcoma or chondrosarcoma, regardless of cytokeratin positivity, as for conventional non-heterologous sarcomatoid mesothelioma.
Posted in Biphasic or Mixed, Causation, Diagnosis & Differentiation, Epithelioid, Full Archive, General, Immunohistochemistry or IHC, Peritoneal (Abdominal Mesothelioma), Pleural, Sarcomatoid, Survival, Type of Assessment:, Type of Mesothelioma: | No Comments »
June 27th, 2008. Malignant Pleural Mesothelioma With Osseous Metastases and Pathologic Fracture of Femoral Neck
Hematogenous or lymphatic metastasis is not uncommon; however, metastasis to bone has rarely been well documented. This is a case report of malignant pleural mesothelioma metastatic to the femur with a pathologic fracture of femoral neck.
June 26th, 2008. Coalescent pleural malignant mesothelioma and adenocarcinoma of the lung, involving only minor asbestos exposure
The former was positive for adenocarcinoma markers such as CEA, Ber-EP4, PE-10, thyroid transcription factor-1 and Napsin A, and negative for mesothelial markers including calretinin, D2-40, WT-1 and HBME, while the latter was the opposite, resulting in a diagnosis of coalescing malignant mesothelioma and adenocarcinoma. The panel of antibodies used for immunohistochemistry was useful to distinguish the two different components in the one tumor.
June 26th, 2008. Induction of apoptosis by intrapleural perfusion hyperthermo-chemotherapy for malignant pleural mesothelioma
Conclusion: In patients with malignant pleural mesothelioma, intrapleural perfusion hyperthermo-chemotherapy induced potent apoptosis of tumor cells, increasing immediately postperfusion and peaking at 24 h.
June 24th, 2008. Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response
Priming of autologous T cells by DCs loaded with MV-infected MPM cells led to a significant proliferation of tumor-specific CD8 T cells. Altogether, these data strongly support the potential of oncolytic MV as an efficient therapeutic agent for mesothelioma cancer.
June 24th, 2008. Asbestos Burden Predicts Survival in Pleural Mesothelioma
Conclusion: Our data suggest that patient survival is associated with asbestos fiber burden in MPM and is perhaps modified by susceptibility.
June 24th, 2008. Chemotherapy of malignant pleural mesothelioma: have we made any progress?
Besides first-line therapy, there are also data to support the efficacy of chemotherapy in pretreated patients. In spite of the various results of preclinical trials which support the prognostic significance of certain targeted structures of intra- and intercellular signal transduction, no relevant efficacy could be shown for targeted therapies in mesothelioma up to now.
June 11th, 2008. Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials
Apart from slightly worse haematological toxicity, there was no significant difference in outcome or toxicity between age groups. The PC regimen is effective and well tolerated in selected elderly patients with MPM.
Posted in Carboplatin, Causation, Chemotherapy, Determining Efficacy, Diagnosis & Differentiation, Epidemiological, Full Archive, Immunohistochemistry or IHC, Occupational Asbestos Exposure, Pemetrexed (Alimta), PET Scan, Pleural, Treatment, Type of Assessment: | No Comments »
June 6th, 2008. Uroplakin is not a Reliable Immunohistochemical Marker for Malignant Mesothelioma of the Pleura
Conclusions: At an antibody dilution for which positive and negative control tissues stain appropriately, PMM does not stain for URO. At higher antibody concentrations, PMM exhibits nonspecific cytoplasmic staining. We assert that URO is not a useful immunohistochemical marker for the detection of PMM. Further studies addressing whether URO is overexpressed at the mRNA level in PMM are warranted.
June 6th, 2008. Long-term mortality from pleural and peritoneal cancer after exposure to asbestos: Possible role of asbestos clearance
The risk for pleural cancer, rather than showing an indefinite increase, might reach a plateau when a sufficiently long time has elapsed since exposure. The different trends for pleural and peritoneal cancer might be related to clearance of the asbestos from the workers' lungs.
Posted in Causation, Determining Efficacy, Diagnosis & Differentiation, Epidemiological, Full Archive, Imatinib Mesylate (Gleevec/Glivec), Intraperitoneal Chemotherapy, melphalan, Occupational Asbestos Exposure, Oxaliplatin (Eloxatin), paclitaxel, PET Scan, Pleural, Pleural Catheters, Proton Beam Therapy, Staging, Symptoms & Symptom Management, Treatment, Type of Assessment: | No Comments »
June 5th, 2008. Response of a Patient with Pleural and Peritoneal Mesothelioma after Second-Line Chemotherapy with Lipoplatin and Gemcitabine
Treatment with lipoplatin-gemcitabine was decided on in November 2006, and the patient showed important improvement in the clinical status and peritoneal effusion. He survived for 36 weeks, with symptom-free survival of 34 weeks.
Posted in Case Study, Chemotherapy, Cisplatin (Platinol ®), Diagnosis & Differentiation, Epithelioid, Full Archive, Gemcitabine (Gemzar), Pleural, Pleural Biopsy, Staging, Symptoms & Symptom Management, thoracoscopy, Treatment, Type of Assessment:, Type of Mesothelioma:, Vinorelbine | No Comments »
June 4th, 2008. Pulmonary Paragonimiasis with Coincidental Malignant Mesothelioma
Here, we report a very rare case of malignant mesothelioma with a concomitant infection of parasitic lung fluke. Keywords: paragonimiasis, malignant mesothelioma, eosinophilia.
May 20th, 2008. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma
Weekly vinorelbine appeared to have a reasonable response rate with an acceptable toxicity profile in the second-line treatment of MPM. Its use should be prospectively evaluated in a randomised trial in the first or second-line therapy of MPM.
May 20th, 2008. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial
Interpretation: The addition of chemotherapy to ASC offers no significant benefits in terms of overall survival or quality of life. However, exploratory analyses suggested that vinorelbine merits further investigation.
Posted in Chemotherapy, Cisplatin (Platinol ®), Determining Efficacy, Full Archive, mitomycin-C, Pleural, Radiation, Survival, Symptoms & Symptom Management, Treatment, Type of Assessment:, Type of Mesothelioma:, Vinorelbine | No Comments »
|
|  |
